[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anticoagulants-and-bleeding-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anticoagulants-and-bleeding-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,80,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100607057","comparison-of-heparin-anti-xa-activity-from-central-venous-catheter-samples-using-a-5-ml-syringe-flush-or-a-vacuum-tube-flush-versus-peripheral-vein-samples-in-icu-patients-100607057",false,"NCT07183605","Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients","Central Catheter Anti-Xa Sampling Study for Accurate aNalysis and Reliable Dosage Assessment","CASSANDRA","Inclusion Criteria:\n\n* Person (or support person\u002Frelative if unable to do so) who has agreed to participate in the study\n* 18 years of age or older\n* Hospitalized in intensive care medicine\n* Having a central venous catheter with at least three lumens (internal jugular, subclavian or femoral) already in place\n* Receiving continuous intravenous unfractionned heparin, with target Anti-Xa activity between 0.3 and 0.7 IU\u002Fml.\n\nExclusion Criteria:\n\n* Protected person (under guardianship or curatorship)\n* Person under court protection\n* Person deprived of liberty\n* Person not affiliated to the French social security\n* Pregnant or breast-feeding woman","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal is to investigate whether blood samples drawn from a central venous catheter can provide reliable measurements of unfractionated heparin (UFH) anti-Xa activity, compared to the standard method of peripheral vein puncture, in intensive care unit (ICU) patients receiving continuous intravenous UFH.\n\nTo evaluate the reliability of central venous blood sampling, the study will compare anti-Xa activity levels obtained simultaneously from two different types of blood draws: one from a peripheral vein (reference method), and the other from the central line using one of two flushing techniques.\n\nThe two central flushing techniques being studied are:\n\n* A 5 mL syringe flush performed over 5 seconds, followed by blood collection.\n* A vacuum tube flush that draws and discards 5 mL of blood, followed by blood collection.\n\nEach patient will undergo four pairs of simultaneous blood draws, using both central techniques in a randomized sequence. The main objective is to assess whether the anti-Xa levels from central samples are equivalent to those from peripheral vein puncture, with a predefined margin of equivalence of ±0.05 IU\u002FmL.\n\nFindings from this study may support the use of central venous catheters for routine anti-Xa monitoring in ICU patients, potentially avoiding painful or technically difficult peripheral vein punctures.",[27],"Anticoagulants and Bleeding Disorders",[29,30,31,32,33],"Unfractionated Heparin","Anti-Xa Activity","Catheterization, Central Venous","Blood Specimen Collection","Intensive care","RECRUITING","2025-11-24",{"date":37,"type":38},"2025-11-25","ACTUAL",{"date":40,"type":38},"2025-09-22",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Centre Hospitalier Régional d'Orléans","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100582862","prospective-observational-pilot-study-of-lmwh-versus-ufh-as-ecmo-anticoagulation-in-lung-transplantation-100582862","NCT06868823","Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation: A Prospective, Observational, and Pilot Study","LUX-ET-LT","Inclusion Criteria:\n\n1. ⃣ Adults (≥18 years old).\n2. ⃣ Patients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support.\n3. ⃣ Planned perioperative anticoagulation with either UFH or LMWH, as determined by the attending anesthesiologist.\n4. ⃣ Ability to provide informed consent or consent provided by a legally authorized representative.\n\nExclusion Criteria:\n\n1. ⃣ Patients receiving ECMO as a bridge to lung transplantation.\n2. ⃣ Patients requiring postoperative continuation of ECMO.\n3. ⃣ Patients with perioperative blood loss ≥3,000 mL.\n4. ⃣ Patients undergoing lung re-transplantation.\n5. ⃣ History of severe coagulopathy or bleeding disorder.\n6. ⃣ Active use of antiplatelet or anticoagulant therapy (excluding study anticoagulants).\n7. ⃣ Known heparin-induced thrombocytopenia (HIT).\n8. ⃣ Severe liver dysfunction (Child-Pugh C) or end-stage renal disease requiring dialysis.\n9. ⃣ Pregnant or breastfeeding women.",{"count":56,"type":21},40,"OBSERVATIONAL","The aim of this observational pilot study is to evaluate the effectiveness and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) as anticoagulation in perioperative ECMO during bilateral lung transplantation.\n\nThe main question this study seeks to answer is:\n\nDoes LMWH provide a safe and effective alternative to UFH for ECMO anticoagulation in lung transplantation, with reduced bleeding and thrombotic complications?\n\nPatients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support will be assigned to one of two anticoagulation strategies:\n\nUFH group: Standard UFH anticoagulation monitored using ROTEM. LMWH group: Enoxaparin-based anticoagulation monitored using ROTEM. The study will assess perioperative blood loss, hemoglobin levels, transfusion needs, and thrombotic events. Additional analyses will include coagulation profile assessments using point-of-care (POC) tests, thrombin generation test (TGT), and laboratory coagulation parameters.",[60,61,27],"Lung Transplantation","Extracorporeal Membrane Oxygenation (ECMO)",[60,61,63,64,65,66,67,68,69,70],"Anticoagulation","Low-Molecular-Weight Heparin (LMWH)","Unfractionated Heparin (UFH)","Thrombosis Prevention","Bleeding Complications","Coagulation Management in Surgery","Hemorrhagic and Thrombotic Events","Perioperative Hemostasis","2025-06-09",{"date":73,"type":38},"2025-06-10",{"date":75,"type":38},"2025-05-01",{"date":77,"type":21},"2025-12-31",{"name":79,"class":45},"University Hospital, Motol",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":46},"100512007","caudal-analgesia--anticoagulated-patient-100512007","NCT05946850","Caudal Analgesia & Anticoagulated Patient","Caudal Analgesia in Anticoagulated Chronic Pain Patients","Inclusion Criteria:\n\n* adult chronic pain patients who undergo caudal analgesia\n\nExclusion Criteria:\n\n* chronic pain patients who refuse caudal analgesia",true,"20 Years","99 Years",{"count":91,"type":21},100,"Caudal analgesia is an effective intervention for lumbosacral pain. Some chronic pain patients take anticoagulants for vasculopathy treatment. Anticoagulation limits the use of caudal analgesia because of the risk of epidural bleeding. Caudal analgesia may be safe and effective in anticoagulated chronic pain patients.\n\nQuantitative analysis of prospective clinical data. Evaluation of caudal analgesia efficacy and safety in anticoagulated chronic pain patients. Analysis of outcome, and complications.",[94,27],"Lumbar Pain Syndrome",[96],"Caudal analgesia","2025-01-23",{"date":99,"type":38},"2025-01-27",{"date":101,"type":38},"2008-01-02",{"date":77,"type":21},{"name":104,"class":45},"Salem Anaesthesia Pain Clinic",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100550843","phase-4-tranexamic-acid-to-decrease-heavy-menstrual-bleeding-in-individuals-anticoagulated-for-venous-thromboembolism-pilot-study-100550843","NCT06452342","TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study","T-REX HMB","Inclusion Criteria:\n\n1. Adult pre-menopausal individuals with regular menstrual cycles (defined as menstrual bleeding every 24 to 38 days)\n2. Diagnosed with acute VTE on objective imaging;\n3. Within two weeks of starting treatment with therapeutic dose anticoagulation;\n4. Planned treatment of at least 3 months of therapeutic dose anticoagulation.\n5. Written informed consent in accordance with federal, local and institutional guidelines.\n\nExclusion Criteria:\n\n1. Hypersensitivity or allergy to TXA\n2. Active major bleeding other than menstrual bleeding\n3. Use of hormonal contraceptives\n4. Known history of thrombosis and antiphospholipid syndrome (including those patients that are triple positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies.\n5. Known renal insufficiency\n6. Pregnant or breastfeeding\n7. Use of other thrombotic agents\n8. Under 18 years of age\n9. Patient is unable to provide informed consent (lacking capacity, language etc)",{"count":113,"type":21},20,[115],"PHASE4","T-REX HMB is a pilot randomized controlled trial (RCT) designed to assess the feasibility of a full trial comparing tranexamic acid (TXA) to placebo in decreasing HMB in premenopausal individuals anticoagulated for VTE. Strong data supports TXA as an effective and safe agent at decreasing HMB in the general population, but its use in those with VTE has been limited by a lack of data for its efficacy in anticoagulated individuals and theoretical concerns of its prothrombotic effects.",[118,119,120,27],"Venous Thromboembolism","Venous Thromboses","Heavy Menstrual Bleeding","NOT_YET_RECRUITING","2024-06-10",{"date":124,"type":38},"2024-06-12",{"date":126,"type":21},"2024-06",{"date":128,"type":21},"2026-04",{"name":130,"class":45},"University Health Network, Toronto"]